Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.00 875,782 08:00:19
Bid Price Offer Price High Price Low Price Open Price
5.75 6.25 6.00 5.875 6.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.15 -12.40 25.00 0.2 25
Last Trade Time Trade Type Trade Size Trade Price Currency
15:21:17 O 250,000 6.05 GBX

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Share Charts

1 Year Midatech Pharma Chart

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

1 Month Midatech Pharma Chart

Intraday Midatech Pharma Chart

Intraday Midatech Pharma Chart

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
20/9/201910:00Midatech Pharma (MTPH) sees 10-fold increase781
30/4/201921:51Midatech Pharma (MTPH) One to Watch 2
03/1/201712:41Midatech Pharma PLC181

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Midatech Pharma Daily Update: Midatech Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 6p.
Midatech Pharma Plc has a 4 week average price of 5.03p and a 12 week average price of 5p.
The 1 year high share price is 19p while the 1 year low share price is currently 2.55p.
There are currently 409,399,613 shares in issue and the average daily traded volume is 565,057 shares. The market capitalisation of Midatech Pharma Plc is £24,563,976.78.
ih_433513: Still they haven’t announced which option for MTD201 they are pursuing. With time and money being of the essence it really beggars belief that they are seemingly incapable of making up their minds in a timely fashion. It seems blatantly obvious to me that the differentiated approach is the way to go. No wonder the share price is slipping - we have a Board incapable of making vital decisions. We simply cannot afford further delays in this process or we’ll run out of money before the trial(s) have been completed. In God’s name get on with it.
mam fach: Exactly. Think MTP recovered to be 22% up last night. This re-alignment of share price with MTP is a red herring. IMHO
mam fach: Looks like MTP is coming down to align with MTPH. Was hoping the reverse might happen. Probably know next few weeks which way share price is going.
nerdofsteel: It appears there may have been a stress / forced seller last week which may explain the share price movement. If cleared it could rise from here. hxxps://
pilkersa: Share price action here is really incomprehensible. Think I will hold for a while. At least sar is starting to look up....
mam fach: Lower price seems to be bringing in fresh buyers. Hope I was lucky to have top up @ under 7.5p. Won't know till later. No idea where share price is going.
tomboyb: To me this looks like going 7p+ pretty soon - hxxp:// NASDAQ value -
jamtomorrow2: You said it. It’s not bioequivalent - but it is potentially better. The problem is that you will have to prove that to the FDA in a large Phase 3 trial. That’s going to cost time and big money, which Midatech doesn’t have. It will therefore need to partner the product and take upfronts and royalties as opposed to keeping 100% control of the product and selling it through Dara. The mathematics of all this are far from straightforward hence the modest share price reaction.
jamtomorrow2: Another new low. Those peak sales forecasts for both MTD201 and the brain cancer drug look pure fantasy to me. Sandostatin is not patent protected anymore and it looks like three generics will be on the market before MTD201 is launched in 2020. The price by that time will be way lower than now - something that the forecasts haven’t taken into account. Also the brain cancer drug has such a limited market that I have no idea how they have arrived at their figures. Bearing in mind that DARA seems to be incapable of marketing its existing drugs it’s very hard to fathom how they will be capable of selling 10-15 times the current sales level. Also what happens to the recently negotiated loan if MTD201 fails to achieve bioequivalence? We haven’t been told the terms and conditions attached to the loan but one would assume that it would be subject to meeting certain drug development goals and surely MTD201 bioequivalence is one of those goals. Would the loan then have to be repaid quickly leaving MTPH in desperate need of new cash just as the share price crashes further? Continous delays and a plethora of unanswered questions surround this company.
hutch_pod: Did you see this from 17th? hTtp:// High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term
Midatech Pharma share price data is direct from the London Stock Exchange
Your Recent History
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191021 04:38:35